Institution
Mahidol University
Education•Bangkok, Nakhon Pathom, Thailand•
About: Mahidol University is a education organization based out in Bangkok, Nakhon Pathom, Thailand. It is known for research contribution in the topics: Population & Malaria. The organization has 23758 authors who have published 39761 publications receiving 878781 citations.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: 2 hitherto unsuspected features of P vivax invasion, a narrow preference for immature reticulocytes and a rapid remodeling of the host cell, provide important insights pertinent to the pathobiology of the P v Vivax infection.
153 citations
••
TL;DR: This method of neurotization produces a result comparable with, if not better than, the results of other types of neurotification in restoration of elbow flexion.
Abstract: Traumatic root avulsion brachial plexus injuries in 216 patients were treated with spinal accessory-musculocutaneous neurotization to restore elbow flexion. The average postoperative follow-up period was 6 years, with a minimum of 2 years for all patients. The percentage of satisfactory biceps recovery (MRC III or better) was 72.5%. The average interval between the operation and MRC III motor recovery was 17 months. The percentage of poor results increased from 25.5% to 62.5% in patients who underwent operation later than 9 months after injury. This method of neurotization produces a result comparable with, if not better than, the results of other types of neurotization in restoration of elbow flexion.
153 citations
••
TL;DR: This article used nanofibrillated cellulose (NFC) to stabilize oil-in-water emulsions, and showed that NFC has a minor effect on lipid digestion and bioaccessibility when used at relatively low levels.
153 citations
••
TL;DR: Artemether-benflumetol (CGP 56 697; Novartis) and artesunate-mefloquine (MFO) were compared in 617 patients with acute uncomplicated multidrug-resistant falciparum malaria on the western border of Thailand.
Abstract: An open, randomized comparison of artemether-benflumetol (CGP 56 697; Novartis) with artesunate-mefloquine was conducted in 617 patients with acute uncomplicated multidrug-resistant falciparum malaria on the western border of Thailand. Both treatments rapidly and reliably cleared fever and parasitemia, and there was no significant difference in the initial therapeutic response parameters. Parasite genotyping was used to distinguish recrudescences from new infections. The 63-day cure rate for artesunate-mefloquine (94%) was significantly higher than the cure rate for artemether-benflumetol (81%) (P < 0.001). Both regimens were well tolerated. Nausea, vomiting, dizziness, sleep disorders, and other neurological side effects were between two and four times more common in the artesunate-mefloquine group than in the artemether-benflumetol group (P < 0.001). Artemether-benflumetol is effective and very well tolerated in the treatment of multidrug-resistant falciparum malaria. A higher dose than that used in the present study may improve efficacy.
153 citations
••
TL;DR: DP was superior to AL for reducing the risk of recurrent parasitemia and gametocytemia, and provided improved hemoglobin recovery, and appears to be a good alternative to AL as first-line treatment of uncomplicated malaria in Uganda.
Abstract: Objectives: To compare the efficacy and safety of artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) for treating uncomplicated falciparum malaria in Uganda. Results: Of 421 enrolled participants, 417 (99%) completed follow-up. The unadjusted risk of recurrent falciparum parasitemia was significantly lower for participants treated with DP than for those treated with AL after 28 d (11% versus 29%; risk difference (RD) 18%, 95% confidence interval (CI) 11%-26%) and 42 d (43% versus 53%; RD 9.6%, 95% CI 0%-19%) of follow-up. Similarly, the risk of recurrent parasitemia due to possible recrudescence (adjusted by genotyping) was significantly lower for participants treated with DP than for those treated with AL after 28 d (1.9% versus 8.9%; RD 7.0%, 95% CI 2.5%-12%) and 42 d (6.9% versus 16%; RD 9.5%, 95% CI 2.8%-16%). Patients treated with DP had a lower risk of recurrent parasitemia due to non-falciparum species, development of gametocytemia, and higher mean increase in hemoglobin compared to patients treated with AL. Both drugs were well tolerated; serious adverse events were uncommon and unrelated to study drugs.
153 citations
Authors
Showing all 23819 results
Name | H-index | Papers | Citations |
---|---|---|---|
Nicholas J. White | 161 | 1352 | 104539 |
Pete Smith | 156 | 2464 | 138819 |
Randal J. Kaufman | 140 | 491 | 79527 |
Kevin Marsh | 128 | 567 | 55356 |
Barry M. Trost | 124 | 1635 | 79501 |
John R. Perfect | 119 | 573 | 52325 |
Jon Clardy | 116 | 983 | 56617 |
François Nosten | 114 | 777 | 50823 |
Paul Turner | 114 | 1099 | 61390 |
Paul Kubes | 109 | 393 | 41022 |
Ian M. Adcock | 107 | 660 | 42380 |
Peter H. Verburg | 107 | 464 | 34254 |
Guozhong Cao | 104 | 694 | 41625 |
Carol L. Shields | 102 | 1424 | 46800 |
Nicholas P. J. Day | 102 | 708 | 50588 |